Nexentis Technologies Inc
NASDAQ:NXTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nexentis Technologies Inc
NASDAQ:NXTS
|
IL |
|
Yesco Holdings Co Ltd
KRX:015360
|
KR |
Nexentis Technologies Inc
N2OFF, Inc. is a cleantech company mainly engaged in European Union (EU) based solar assets using the Ready to Build (RTB) business model. The Company is an investor in four solar projects in three different EU countries. It collaborates with Solterra Renewable Energy Ltd., an Israeli corporation and a wholly owned subsidiary of Solterra Energy Ltd., an Israeli corporation, which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (PV) projects. The Company also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. The Company’s solutions are focused on improving the food safety and shelf life of fresh produce. The Company, through its subsidiary, MitoCareX Bio Ltd., is focused on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family.
N2OFF, Inc. is a cleantech company mainly engaged in European Union (EU) based solar assets using the Ready to Build (RTB) business model. The Company is an investor in four solar projects in three different EU countries. It collaborates with Solterra Renewable Energy Ltd., an Israeli corporation and a wholly owned subsidiary of Solterra Energy Ltd., an Israeli corporation, which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (PV) projects. The Company also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. The Company’s solutions are focused on improving the food safety and shelf life of fresh produce. The Company, through its subsidiary, MitoCareX Bio Ltd., is focused on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family.
